Farkhod Eshboev, Head of the Biotechnology and Bioinformatics Laboratory at the Institute for Advanced Research of the New Uzbekistan University, and Associate Professor at the Department of Chemistry and Materials Engineering, was one of the co-authors of a new study conducted as part of international scientific collaboration.
In the study, researchers investigated the antiviral activity of a compound called 2'-deoxy-2'-fluoro-5-methyl-1-β-D-arabinofuranosyluracil (FMAU) against the monkeypox virus (MPXV) and the vaccinia virus (VACV). Laboratory experiments showed that this compound effectively suppressed viral replication even at very low concentrations, and did not cause significant damage to the tested cells.
One of the key findings of the study was that in experimental mice treated with FMAU, a 100% survival rate was observed against both the monkeypox and vaccinia viruses. Furthermore, the compound was effective in reducing the viral load and demonstrated antiviral activity even when administered orally.
The results of the study were published in the international scientific journal Emerging Microbes & Infections in 2026. The journal is in the Q1 quartile of the Scopus database in several scientific fields (CiteScore: 14.1).
This scientific work provides a crucial basis for further research to study the FMAU compound as a promising antiviral drug candidate against monkeypox and related viral infections. However, additional clinical studies are needed to determine its safety and efficacy in humans.
We congratulate Farkhod Eshboev on this achievement in an international scientific publication and wish him success in his future research endeavors!
O'zbekcha
Русский
English